The chronic e¡ects of glycine transporter1and 2 inhibitors (sarcosine and ALX-1393, respectively) on miniature inhibitory postsynaptic currents were studied in cultured spinal neurons. We found that sarcosine increased the frequency of overall miniature inhibitory postsynaptic currents without a¡ecting the ratio of glycinergic, mixed and GABAergic miniature inhibitory postsynaptic currents, whereas ALX-1393 changed the ratio by increasing the proportions of GABAergic and mixed miniature inhibitory postsynaptic currents without a¡ecting overall mIPSC frequency.We propose that inhibition of glycine transporter 1 by sarcosine increased overall mIPSC frequency via the activation of presynaptic glycine receptors, while inhibition of glycine transporter 2 by ALX-1393 changed the ratio of glycinergic, mixed and GABAergic miniature inhibitory postsynaptic currents by shifting the balance of inhibitory transmitters in vesicles towards g-aminobutyric acid. NeuroReport 16:1227^1231
INTRODUCTION
In the central nervous system (CNS), glycine transporters (GlyTs) play an important role in the maintenance of low extracellular glycine concentration by reuptake of glycine. GlyTs belong to the family of sodium/chloride-dependent transporters, which include GlyT1 and GlyT2 [1] . GlyT1 is widely expressed in glial cells and is thought to control extracellular glycine concentration and regulate excitatory synapses via the glycine-binding site on the N-methyl-Daspartate receptors [2] [3] [4] . GlyT2 is largely localized to the presynaptic terminals of glycinergic neurons in the brainstem and spinal cord [5] , and is thought to provide the principal glycine uptake mechanism at glycinergic synapses. The unique expression patterns of GlyT1 and GlyT2 suggest they perform distinct functions. Indeed, studies on GlyT1 and GlyT2 knockout mice revealed different effects on glycinergic synaptic transmission [6, 7] .
Glycine and g-aminobutyric acid (GABA) are the primary inhibitory neurotransmitters in the CNS. They can be coreleased from the same presynaptic terminal, and even from the same presynaptic vesicle [8] [9] [10] [11] . Furthermore, glycine receptors (GlyRs) and g-aminobutyric acid type A receptors (GABA A Rs) are colocalized at postsynaptic sites in the spinal cord [12] . In addition, glycine and GABA can be carried into synaptic vesicles through the same vesicular inhibitory amino-acid transporter, which does not discriminate between them [13, 14] . Accordingly, the vesicular presence of glycine and GABA depends on the relative concentrations of these transmitters in the cytoplasm. Because GlyT1 and GlyT2 together determine the extracellular and cytoplasmic concentrations of glycine, we ask whether and how GlyT1 and GlyT2 affect inhibitory transmission. To address this question, we examined the chronic effects of GlyT1 and GlyT2 inhibitors on the properties of GABAergic and glycinergic miniature inhibitory postsynaptic currents (mIPSCs) in cultured spinal neurons.
MATERIALS AND METHODS
The care and use of animals in these experiments followed the guidelines and protocols approved by the Institutional Animal Care and Use Committee of the Institute of Neuroscience, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences.
Cultured spinal dorsal horn neurons and chronic treatment: Spinal dorsal horn neurons from 15-day embryonic Sprague-Dawley rats were isolated by a standard enzyme treatment protocol. Briefly, spinal dorsal horns were dissociated by trypsin and plated on cover glasses coated with poly-L-lysine (Collaborative Biomedical Products, Bedford, Massachusetts, USA). The neurons were grown in Dulbecco's modified Eagle's medium (Gibco, Grand Island, New York, USA) with L-glutamine and 10% fetal bovine serum (Gibco) and 10% F-12 nutrient mixture (Gibco) for 24 h. Then, neurobasal medium (1.5 ml, Gibco) with 2% B27 (Gibco) was replaced every 3-4 days. Chronic treatment was begun at day 16 in vitro with application of the GlyT1 inhibitor, sarcosine (N-methylglycine) and the GlyT2 inhibitor, ALX-1393 (O-[(2-benzyloxyphenyl-3-fluorophenyl) methyl]-L-serine). After 2 days of treatment, whole-cell recordings were performed.
Solutions and drugs:
The standard external solution contained (mM): NaCl, 150; KCl, 5; MgCl 2 , 1; CaCl 2 , 2; glucose, 10; N-2-hydroxyethyl piperazine-N 0 -2-ethanesulfonic acid (HEPES), 10; pH 7.3 adjusted with Tris-base. The pipette solution contained (mM): Cs-gluconate, 145; NaCl, 10; ethyleneglycol-bis-(b-aminoethyl ether)N,N,N 0 ,N 0 -tetraacetic acid, 0.2; HEPES, 10; ATP-Mg, 2; pH 7.2. Drugs were rapidly applied using the Y-tube method [15] . During recordings from treated cells, the same concentration of sarcosine or ALX-1393 used for the chronic treatment was added to the external solution. To record mIPSCs, 0.2 mM tetrodotoxin, 10 mM 6-cyano-7-nitroquinoxaline-2,3-dione and 20 mM D-2-amino-5-phosphonovalerate were added to the extracellular solution to block action potentials and glutamatergic responses. In addition, 1 mM QX-314 was added to the pipette solution to block Na + channels. All drugs were from Sigma (St Louis, Missouri, USA).
Electrophysiological recording and data analysis: Wholecell recordings were carried out at room temperature (221C-251C) with an Axopatch 200B amplifier (Axon Instruments, Union City, California, USA), and data were analyzed by Clampfit software (version 9.0, Axon Instruments). The membrane potential was held at 0 mV. Miniature synaptic currents were analyzed using the Mini Analysis Program (version 6.0.3, Synaptosoft Inc., Decatur, Georgia, USA). Cumulative curves were compared using the KolmogorovSmirnov test for significant differences. Differences in mean values were tested by the Student's t-test. All statistical results are given as mean7SEM.
RESULTS
Miniature inhibitory postsynaptic currents recorded from cultured spinal dorsal horn neurons: On day 18 in vitro, neurons showed a resting membrane potential of À52.071.6 mV (n¼11) and the reversal potential of mIPSCs was À56.072.2 mV (n¼9). The mIPSCs of dorsal horn neurons can be mediated by GABA A R, GlyR or a mixture of both [9] [10] [11] (Fig. 1) . Allopregnanolone (AP, 0.1 mM) was applied to prolong the decay time of GABA A R-mediated mIPSCs from 27.271.9 to 39.572.0 ms without affecting their frequency (n¼6), thus enhancing the differences between the mIPSC components [11] . However, AP had no significant effect on the frequency or decay time of GlyRmediated mIPSCs (data not shown).
The mIPSCs of dorsal horn neurons could be separated into three categories on the basis of their decay kinetics ( Fig.  1a) : GlyR-mediated events decayed rapidly with a monoexponential time constant (11.172.2 ms; n¼20); GABA A Rmediated events had a slower monoexponential decay time constant (43.774.7 ms, n¼20); while mixed events had a biexponential decay, whose fast and slow time constants (9.272.7 and 54.476.5 ms, respectively; n¼20) were comparable to those of GlyR-mediated and GABA A R-mediated events (Fig. 1b) . The percentages of GABAergic, mixed and glycinergic mIPSCs under control conditions were 2577%, 1775% and 58710%, respectively (n¼20), indicating that glycinergic mIPSCs constituted the main population in these cultured neurons (Fig. 1c) .
Effects of glycine transporter 1 and 2 inhibitors on miniature inhibitory postsynaptic currents: To determine the effects of sarcosine and ALX-1393 on inhibitory neurotransmission, we first studied the effects of the inhibitors on the resting membrane potential and the reversal potential of mIPSCs. The inhibitors neither changed the resting membrane potential (À52.072.4 mV, n¼8 and À54.071.5 mV, n¼7, for 500 mM sarcosine and 0.2 mM ALX-1393, respectively), nor affected the reversal potential (À55.372.4 mV, n¼8 and À57.272.8 mV, n¼7). However, 500 mM sarcosine changed the frequency of occurrence of mIPSCs from a control value of 0.8670.16 Hz (n¼20) to 1.0670.22 Hz (n¼17), while 0.2 mM ALX-1393 did not change the frequency (0.9270.18 Hz, n¼16). We also examined the effects of the two inhibitors on the ratios among the three kinds of mIPSCs, an indication of the proportions of GABA and glycine in synaptic vesicles. In the presence of AP, the percentages of GABAergic, mixed and glycinergic mIPSCs under control conditions were 2577%, 1775% and 58710%, respectively (n¼20). ALX-1393 (0.2 mM) significantly changed the ratio by increasing the GABAergic and mixed mIPSC components to 3377% and 2171%, and decreasing those of glycinergic mIPSCs to 4677% (n¼16), whereas sarcosine (500 mM) had little effect, with 2175%, 1673% and 6375% (n¼17) for GABAergic, mixed and glycinergic, respectively (Fig. 1c) .
Effects of glycine transporter 1 and 2 inhibitors on glycine receptor mediated miniature inhibitory postsynaptic currents: We then examined the effects of the inhibitors on pure GlyR-mIPSCs and GABA A R-mIPSCs to further distinguish their differential effects. Pure GABA A R-mIPSCs and GlyR-mIPSCs, which were pharmacologically isolated by applying the GlyR antagonist strychnine (0.3 mM) or the GABA A R antagonist bicuculline (10 mM), were recorded in the absence of AP. Sarcosine (500 mM) significantly increased the frequency of GlyR-mIPSCs from a control value of 0.7870.19 Hz (n¼20) to 0.9670.16 Hz (n¼17) without affecting amplitude, decay time or rise time constant (Fig.  2) . By contrast, although 0.2 mM ALX-1393 had a tendency to decrease the frequency of GlyR-mIPSCs (from 0.7870.19 to 0.6670.11 Hz, n¼16), the value was not significantly different from the control value (Fig. 2) . When 0.5 mM ALX-1393 was used, the GlyR-mIPSC frequency was significantly decreased from 0.7870.19 to 0.5370.12 Hz (n¼12). Both concentrations of ALX-1393 had little effect on the amplitude, decay time or rise time constant of GlyRmIPSCs.
Effects of glycine transporter 1 and 2 inhibitors on gaminobutyric acid type A receptor mediated miniature inhibitory postsynaptic currents: We further investigated the effects of the inhibitors on pure GABA A R-mIPSCs in the presence of strychnine (Fig. 3) . Neither sarcosine (500 mM) nor ALX-1393 (0.2 mM) modulated the GABA A R-mIPSC amplitude, decay time or rise time constant. However, the frequency of GABA A R-mIPSCs was significantly increased from a control value of 0.2370.06 Hz (n¼20) to 0.3470.07 Hz (n¼16) and 0.4070.07 Hz (n¼12) by 0.2 and 0.5 mM ALX-1393, respectively. Sarcosine-treated neurons had an mIPSC frequency of 0.2470.06 Hz (n¼17), similar to control.
DISCUSSION
Our results show that inhibitors of GlyT1 and GlyT2 exert different effects on inhibitory transmission in cultured spinal dorsal horn neurons. Neither the GlyT1 inhibitor sarcosine nor the GlyT2 inhibitor ALX-1393 changed the resting membrane potential or the reversal potential of mIPSCs, and had no effect on the amplitudes, decay time or rise time constants of GlyR-mIPSCs and GABA A R-mIPSCs. All these results suggest that the inhibitors of GlyTs do not affect the functions and properties of the receptors, which is consistent with previous studies [16] [17] [18] . In addition, studies on GlyT1-and GlyT2-deficient mice showed the same results [6, 7] . Therefore, we propose that the two inhibitors of GlyTs may exert their effects through presynaptic mechanisms. The inhibitor of glial GlyT1, sarcosine, increased the overall frequency of mIPSCs but did not change the ratios of the three types of mIPSCs. These results indicate that presynaptic release was facilitated after sarcosine treatment in all three glycinergic, GABAergic and mixed synapses. Blockade of GlyT1 by sarcosine could significantly increase the concentration of extracellular glycine. Furthermore, it has been reported that activation of presynaptic glycine receptors enhances transmitter release at a mammalian central synapse [19, 20] . So, we propose that sarcosine treatment inhibited GlyT1, which increased extracellular glycine, which then activated presynaptic GlyRs to cause the increased frequency of mIPSCs. However, examination of pure GlyR-mIPSCs and GABA A R-mIPSCs revealed an enhanced frequency of GlyR-mIPSCs only, not of GABA A RmIPSCs. These mismatched results were a consequence of the different recording conditions. Pure GlyR-mIPSCs and GABA A R-mIPSCs were recorded in the presence of the GABA A R antagonist bicuculline and the GlyR antagonist strychnine, respectively. So, during examination of GABA A R-mIPSCs, the role of presynaptic GlyRs had been abolished by strychnine.
The inhibitor of neuronal GlyT2, ALX-1393, had no effect on overall mIPSC frequency, but significantly changed the ratios of the three kinds of mIPSCs by increasing the proportions of GABAergic and mixed mIPSCs and decreasing that of glycinergic mIPSCs. These results indicate that ALX-1393 changed the components in synaptic vesicles to cause more GABA and less glycine release. Consistent with this interpretation, the frequency of pure GABA A R-mIPSCs was significantly increased by ALX-1393 treatment. Although 0.2 mM ALX-1393 only showed a tendency to decrease the frequency of pure GlyR-mIPSCs, a higher concentration (0.5 mM) significantly decreased this frequency. Blockade of GlyT2 could significantly decrease cytoplasmic glycine concentration, so the relative concentration of GABA versus glycine in the cytoplasm would be elevated. Thus, the balance of glycine and GABA in synaptic vesicles would shift towards GABA, which would lead to the increased proportions and frequencies of GABA A Rmediated mIPSCs. The role of presynaptic GlyRs was not detectable after ALX-1393 treatment, perhaps because an increase of extracellular glycine was not a major consequence of GlyT2 inhibition in the presence of functional GlyT1. Also, it is possible that some vesicles remained effectively empty while the cytoplasmic transmitter concentrations were low, thereby nullifying the expected increase in mIPSC frequency.
CONCLUSION
We conclude that inhibitors of GlyT1 and GlyT2 exert different effects on inhibitory transmission in cultured spinal neurons. We propose that inhibition of GlyT1 by sarcosine increases overall mIPSC frequency through the activation of presynaptic GlyRs, while inhibition of GlyT2 by ALX-1393 changes the ratio of glycinergic, mixed and GABAergic mIPSCs by shifting the balance of glycine and GABA in vesicles in favor of GABA. 
